Find a Clinical Trial

Application of N-of-1 Clinical Trial Design in Rhematoid Arthritis

Application of the N-of-1 Trial Design Paradigm
Rheumatoid Arthritis Protocol

18-65

Learn more

AbCLO Open Abdomen Study

Assessment of a non-invasive device in the management of Open Abdomen – Pilot Study

18-99

Learn more

GORE SYNECOR

Assessment of GORE® SYNECOR Biomaterial in
Focused Patient Populations and Long-Term
Application

18-80

Learn more

Body composition in VLBW infants

Association of body composition in VLBW infants and neurodevelopmental outcomes

No minimum age

Learn more

A Study of the Pharmacokinetics, Safety, and Efficacy of ASTX727

ASTX727-07 - A Single-Arm, Open-Label Pharmacokinetic, Safety, and Efficacy Study of ASTX727 in Combination with Venetoclax in Adult Patients with Acute Myeloid Leukemia

18+

Learn more

ARCADIA

AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke

45+

Learn more

Breast Cancer Database

Breast Cancer Database

18+

Learn more

C2D2AI Participant Recruitment Feasibility Study

C2D2AI Participant Recruitment Feasibility Study

50+

Learn more

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (CAMBRIA-1)

CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence

18+

Learn more

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/​HER2- Early Breast Cancer (CAMBRIA-2)

CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease

18+

Learn more